Monoclonal Gammopathy of Renal Significance (MGRS)

Article written and reviewed by Dr Luca Moretti

Monoclonal Gammopathy of Renal Significance (MGRS) comprises renal lesions caused by a monoclonal immunoglobulin through deposition or indirect mechanisms, produced by a B-cell or plasma-cell clone that does not meet independent hematologic criteria for initiating antineoplastic therapy.

MGRS represents an intermediate clinical situation between monoclonal gammopathy of undetermined significance (MGUS) and overt neoplastic plasma-cell dyscrasias and is distinguished by its clinical and prognostic relevance. Although patients do not meet conventional criteria for antineoplastic therapy based on tumor burden, they develop potentially irreversible kidney injury that may progress to end-stage renal disease if not treated early.

From a pathogenetic standpoint, monoclonal proteins produced by the clone, although often present at low serum concentrations and without systemic symptoms, may be highly nephrotoxic and trigger injury through glomerular, tubular, interstitial or vascular deposition or through indirect mechanisms.
The renal lesions associated with MGRS are extremely diverse and include proliferative glomerulonephritis with monoclonal immunoglobulin deposits, monoclonal gammopathy-associated C3 glomerulopathy, light- or heavy-chain deposition disease (LCDD, HCDD), AL amyloidosis, nonamyloid fibrillary deposition disorders such as immunotactoid glomerulopathy and rare truly monotypic fibrillary glomerulonephritides, monoclonal cryoglobulinemia and other rare forms.

From an epidemiologic standpoint, the true prevalence of MGRS is probably underestimated because the nosologic definition is relatively recent and diagnosis is difficult; its frequency depends on the population studied and on indications for kidney biopsy. It is observed mainly in older individuals, in whom monoclonal gammopathies are more frequent, but may also occur at younger ages.

Diagnosis is often delayed because systemic symptoms are limited and the monoclonal component may be small, but prognosis depends closely on early recognition and initiation of treatment directed at the responsible clone. Failure to recognize and treat MGRS carries a high risk of progression to end-stage chronic kidney disease and increased mortality, making it one of the more insidious and underdiagnosed secondary nephropathies.

Etiology, pathogenesis and pathophysiology

The etiology of MGRS lies in the pathologic production of monoclonal immunoglobulins or their fragments by an expanded clone of B cells or plasma cells, generally without the features of an overt hematologic malignancy.

Most cases of MGRS arise in association with monoclonal gammopathy of undetermined significance (MGUS), but the condition may also occur with low-grade B-cell lymphomas, solitary plasmacytomas, indolent Waldenstrom macroglobulinemia or other plasma-cell dyscrasias that have not evolved to an overt malignant stage.

The responsible monoclonal proteins may belong to any isotype, including IgG, IgA, IgM and rarely IgD or IgE, and may consist of light chains, kappa or lambda, or heavy chains. The serum monoclonal component is often quantitatively small but may nevertheless be sufficient to cause substantial renal damage.

No specific risk factors for MGRS have been defined beyond the presence of a monoclonal gammopathy or a small B-cell/plasma-cell clone; advanced age increases the likelihood of identifying such clones.
However, only a minority of individuals with MGUS develop clinically significant MGRS nephropathy, suggesting that specific molecular properties of the immunoglobulin produced have an important role.

From a pathogenetic standpoint, MGRS develops through direct and/or indirect toxic effects of monoclonal immunoglobulins or their fragments on renal tissues.

The principal pathogenetic mechanisms include:

• Glomerular deposition of monoclonal immunoglobulins or immune complexes, which may cause glomerular inflammation, as in proliferative glomerulonephritis with monoclonal deposits.
• Tissue deposition along glomerular, tubular and vascular basement membranes, with distribution varying by disease; glomerular and tubular deposits are frequent in LCDD/HCDD, whereas glomerular involvement is common in AL amyloidosis.
• Formation of fibrillar or microtubular structures, as in immunotactoid glomerulopathy and rare fibrillary glomerulonephritides with truly monotypic deposits, causing direct glomerular basement membrane injury and impaired filtration.
• Complement activation and local inflammatory pathways, promoted by some abnormal immunoglobulins that act as autoantibodies or disturb the balance between activation and regulation of the complement system, as in monoclonal gammopathy-associated C3 glomerulopathy.
• Cryoglobulin precipitation in renal capillaries, typical of type I monoclonal cryoglobulinemia, with vascular occlusion and tissue ischemia.

The extent and site of deposition or toxic activity of monoclonal immunoglobulins determine the heterogeneity of the clinical and histologic manifestations of MGRS. Some patients predominantly develop nephrotic syndrome with massive proteinuria, hypoalbuminemia and edema; others present with rapidly progressive acute or chronic renal failure, hematuria, arterial hypertension or, less commonly, a nephritic syndrome.

At the pathophysiologic level, renal injury results from interaction among the amount and structural and biochemical characteristics of the monoclonal protein, individual patient susceptibility, renal handling of immunoglobulins and the local inflammatory response.

In nonamyloid deposition MGRS (LCDD, HCDD), immunoglobulins deposit in glomerular basement membranes and tubules, causing progressive thickening and sclerosis with evolution toward chronic kidney disease.

In AL amyloidosis, formation of insoluble fibrils progressively disrupts renal architecture.

In monoclonal gammopathy-associated C3 glomerulopathy, the monoclonal protein may, in some patients, interfere with regulators of the alternative complement pathway and promote activation; this mechanism cannot be demonstrated in every case.

The course is variable: without clonal control, kidney injury may progress and become irreversible, but the rate of progression and potential for recovery depend on the specific lesion, initial severity and depth of hematologic response.

Overall, MGRS is a paradigmatic model of organ damage caused by an indolent hematologic clone, in which early recognition and understanding of pathogenetic mechanisms are essential for targeted treatment and improved renal and overall prognosis.

Clinical manifestations

The clinical manifestations of Monoclonal Gammopathy of Renal Significance (MGRS) reflect the marked heterogeneity of pathogenetic mechanisms and histologic lesions associated with the various monoclonal immunoglobulin-related nephropathies. Presentation varies considerably according to the type of deposit, amount of monoclonal protein, site and extent of renal damage and individual patient characteristics.

In most cases, MGRS presents as a glomerular nephropathy with proteinuria of variable severity, often in the nephrotic range (>3.5 g/day), accompanied by generalized edema, especially dependent and periorbital. Protein loss may be associated with hypoalbuminemia, hypercholesterolemia and persistent edema typical of nephrotic syndrome. In some patients, proteinuria is lower and may be subnephrotic or intermittent.

Acute or chronic kidney failure is frequent and may progress rapidly, especially in tubulointerstitial deposition disorders or proliferative glomerulonephritis. Decline in renal function may be insidious or present with a rapid rise in serum creatinine, oliguria and fluid retention. Arterial hypertension is common and may be difficult to control because of both renin-angiotensin system activation and reduced functioning nephron mass.

Urinary abnormalities include persistent microscopic hematuria, occasionally macroscopic hematuria, red blood cell casts and, in some cases, sterile leukocyturia. Urinary sediment may be active, with erythrocytes, leukocytes and casts, in proliferative glomerulonephritis, or relatively bland in predominantly interstitial deposition disease.

Some specific forms of MGRS have characteristic manifestations:

• membranoproliferative glomerulonephritis associated with monoclonal immunoglobulins: typically presents with nephrotic proteinuria, hematuria and progressive deterioration of renal function.
• light- or heavy-chain deposition disease (LCDD, HCDD): often presents with progressive renal failure and proteinuria and may be associated with severe hypertension, microscopic hematuria and sometimes isolated nephrotic syndrome.
• renal AL amyloidosis: dominated by massive nephrotic proteinuria, with risk of deep vein thrombosis, infections and other complications of nephrotic syndrome.
• C3 glomerulopathy associated with monoclonal gammopathy: may present with acute nephritic syndrome, macroscopic hematuria, hypertension and rapid reduction of renal function, together with persistent hypocomplementemia.
• monoclonal cryoglobulinemias: systemic manifestations such as Raynaud phenomenon, digital ulcers, purpura and acrocyanosis are typical, together with rapidly progressive membranoproliferative glomerulonephritis.

Some patients may also have extrarenal manifestations related to the monoclonal protein, such as peripheral neuropathy or cutaneous signs of vasculopathy. Hepatomegaly, lymphadenopathy, splenomegaly and cytopenias may instead reflect the underlying hematologic disease or other conditions and should not automatically be attributed to the monoclonal protein. In most MGRS cases, however, systemic symptoms are absent or subtle and the disorder is suspected after detection of apparently idiopathic renal injury resistant to conventional therapy.

The clinical course of MGRS is often progressive: without treatment directed at the underlying gammopathy, renal damage may evolve toward diffuse glomerulosclerosis, irreversible loss of renal function and the need for renal replacement therapy with dialysis or kidney transplantation. In more indolent cases progression may be slow but relentless, with gradual loss of glomerular function and development of metabolic complications.

The variability of clinical presentation, absence of obvious systemic symptoms and low serum concentration of the monoclonal component make MGRS a frequently underdiagnosed and insidious condition. Early diagnosis and awareness of the possible association between monoclonal gammopathy and kidney injury are essential to improve prognosis and prevent irreversible complications.

Investigations and diagnosis

The diagnosis of MGRS is complex and requires integration of clinical, laboratory, immunochemical, histologic and often molecular data.

Suspicion should arise in the presence of renal damage without a clear alternative explanation, including proteinuria, renal failure, nephrotic or nephritic syndrome or rapidly progressive glomerulonephritis, associated with detection, even at low concentration, of a serum or urine monoclonal component in a patient who does not meet criteria for an overt hematologic malignancy.

The initial assessment includes basic and specific laboratory tests: serum creatinine and renal function, 24-hour proteinuria, urinary sediment, albumin, lipid profile, electrolytes, serum complement C3 and C4, viral serology for HBV, HCV and HIV, and general hematologic tests. Nephrotic-range proteinuria, hematuria, persistent hypocomplementemia or rapidly progressive kidney failure in association with a monoclonal component should prompt consideration of MGRS.

The search for a monoclonal component is performed with serum and urine electrophoresis and immunofixation, measurement of serum immunoglobulins (IgG, IgA, IgM), quantification of free light chains (kappa and lambda) and calculation of their ratio. The monoclonal component is often small and may escape standard testing, so assay sensitivity and clinical suspicion must be high.

The fundamental investigation for diagnosing MGRS is kidney biopsy, which identifies the histopathologic lesion and directly relates renal injury to the monoclonal protein. Major lesions include membranoproliferative patterns with monoclonal deposits, light- or heavy-chain deposition disease (LCDD, HCDD), AL amyloidosis, immunotactoid glomerulopathy and rare fibrillary glomerulonephritides with truly monotypic deposits, monoclonal gammopathy-associated C3 glomerulopathy and other rare entities. Analysis by light microscopy, immunofluorescence and electron microscopy is essential to determine the nature, distribution and composition of deposits.

Mass spectrometry is particularly useful in uncertain, discordant or unclassifiable cases with immunofluorescence or immunohistochemistry, especially for amyloid typing; it is not necessary in every biopsy with conclusive findings.

At the same time, a complete hematologic evaluation with bone marrow aspiration and biopsy, immunophenotyping, cytogenetic and molecular studies is essential to identify the responsible clone and exclude an overt hematologic malignancy such as multiple myeloma, Waldenstrom macroglobulinemia or aggressive B-cell lymphoma.

The diagnosis of MGRS requires:

• a renal lesion caused by a monoclonal immunoglobulin through a direct or indirect mechanism, generally defined by kidney biopsy;
• hematologic evaluation of the responsible clone, which may be very small or not identifiable by standard tests;
• absence of an independent hematologic indication for treatment based solely on tumor burden, despite renal injury attributable to the monoclonal protein;
• exclusion of alternative renal causes that better explain the clinical and histologic findings.

Supportive markers include hypocomplementemia, nephrotic proteinuria, rapidly progressive kidney failure, a suggestive clinical picture and a typical distribution of deposits on kidney biopsy, but diagnosis requires that the renal lesion be attributable to the monoclonal protein; some forms of MGRS act through indirect mechanisms and have no demonstrable monoclonal deposits.

Additional second-level investigations may include renal ultrasound, abdominal CT and whole-body PET/CT to assess possible extrarenal lesions or occult neoplastic sites, cardiac assessment when amyloidosis is suspected, cerebrospinal fluid examination in the presence of neurologic symptoms and genetic testing when a complement-regulatory defect is suspected.

Early and accurate diagnosis of MGRS is crucial for timely treatment aimed at suppressing production of the monoclonal protein and preventing progression to end-stage renal disease, one of the major adverse renal outcomes in this population.

Treatment and prognosis

Treatment of MGRS requires early and selective suppression of the clone responsible for producing the nephrotoxic monoclonal protein, even in the absence of tumor-burden criteria defining an overt hematologic malignancy; the goal is to preserve or, when possible, recover renal function.

Current international guidelines recommend an individualized therapeutic approach based on the histopathologic features of the nephropathy, the type of responsible clone, B-cell or plasma-cell, the extent and severity of kidney damage, age and comorbidities.

In cases with a plasma-cell clone, for example light-chain deposition disease or AL amyloidosis, regimens derived from multiple myeloma treatment are used, including bortezomib (a proteasome inhibitor), dexamethasone and cyclophosphamide in CyBorD, possibly combined with daratumumab (an anti-CD38 antibody), and sometimes lenalidomide or other immunomodulatory agents, with intensity and duration adjusted to renal vulnerability.

In cases with a lymphocytic clone, treatment is guided by clonal characteristics and renal function and may include rituximab-based regimens, bendamustine or cyclophosphamide, or Bruton tyrosine kinase inhibitors in appropriate clones; there is no single regimen suitable for all MGRS.

High-dose chemotherapy with autologous hematopoietic stem cell transplantation may be considered in selected eligible patients, especially in plasma-cell forms. Advanced renal impairment or dialysis requires specialist assessment and adaptation of conditioning but is not, by itself, an absolute exclusion criterion.

A distinctive feature of MGRS is that therapy is indicated even without classic criteria for hematologic malignancy because of the need to prevent end-stage kidney failure. Treatment intensity must be calibrated to renal and systemic toxicity risk: in advanced renal impairment, drug selection and dosage must be adapted to the individual agent, because some require dose reductions while others, such as bortezomib, do not require standard renal dose adjustment.

Supportive therapies are fundamental and include blood-pressure control, reduction of proteinuria with ACE inhibitors or angiotensin receptor blockers, treatment of edema, prevention of thromboembolic complications especially in nephrotic syndrome, correction of electrolyte disturbances and malnutrition, monitoring of electrolytes and renal function, and management of infections and metabolic complications.
In AL amyloidosis, supportive measures require particular attention to orthostatic hypotension, cardiac complications and maintenance of fluid and electrolyte balance.

In selected cases of severe type I cryoglobulinemia or hyperviscosity, plasma exchange may be considered as a temporary measure; it is not a general therapy for MGRS and must be combined with clonal control.

The prognosis of MGRS depends closely on the speed and depth of hematologic response, timeliness of diagnosis and extent of renal damage when treatment begins. When treated promptly, hematologic remission and partial or complete recovery of renal function may occur. In late-diagnosed disease or when renal damage is already advanced, progression to end-stage kidney disease and the need for dialysis or transplantation remain frequent.

Follow-up requires regular monitoring of the serum and urinary monoclonal component, renal function, proteinuria, urinary sediment and relevant organ-response markers such as NT-proBNP, complement levels and hematologic parameters, together with close multidisciplinary collaboration among nephrologists, hematologists and other specialists.

MGRS relapse may occur after an initial response or after kidney transplantation, often because monoclonal immunoglobulin production persists or recurs. In such cases, renewed treatment of the pathologic clone is necessary, sometimes using salvage strategies or investigational agents.

Overall, management of MGRS requires a highly individualized and multidisciplinary approach aimed both at controlling the underlying hematologic disorder and preserving renal function while preventing long-term complications.

Complications

The complications of Monoclonal Gammopathy of Renal Significance (MGRS) are crucial determinants of prognosis and quality of life. They result from direct monoclonal immunoglobulin-mediated damage to renal tissues, the consequences of loss of kidney function and adverse effects of antineoplastic and supportive treatments.

The most serious and frequent complication is progression to end-stage chronic kidney disease. Without timely and appropriate treatment, progression may be substantial and, in some lesions, rapid, leading to chronic dialysis and increased medium- and long-term mortality. Irreversible renal-function loss also increases the risk of cardiovascular, metabolic and infectious complications.

Nephrotic syndrome and refractory edema are common in glomerular deposition disorders such as LCDD, HCDD, AL amyloidosis and membranoproliferative glomerulonephritis and promote bacterial and fungal infections through loss of immunoglobulins and complement proteins, deep vein thrombosis and pulmonary thromboembolism because of hypercoagulability, hypercholesterolemia and protein malnutrition. These complications may further worsen the clinical course and reduce survival.

Systemic involvement may include extrarenal manifestations related to the monoclonal protein, such as polyneuropathy, hepatomegaly and hematologic abnormalities, particularly in AL amyloidosis or monoclonal cryoglobulinemia, with risk of heart failure, arrhythmias, worsening peripheral neuropathy, Raynaud phenomenon and ischemic skin lesions.

Infectious complications are an important cause of morbidity and mortality: immunoglobulin loss in nephrotic syndrome, immunosuppression induced by antineoplastic treatment and the presence of dialysis venous catheters increase the risk of severe infection, sepsis, opportunistic infection and reactivation of latent infections.

Hematologic and iatrogenic complications may include myelosuppression, cytopenias such as anemia, leukopenia and thrombocytopenia, renal, hepatic, cardiac or neurologic organ toxicity, allergic reactions and, with some treatments, a variable risk of secondary malignancies. Patients undergoing autologous stem cell transplantation are at particularly high risk of infectious and toxic complications and require intensive monitoring and preventive strategies.

Another characteristic complication is recurrence of MGRS after kidney transplantation: persistence or recurrence of the clone may cause new deposits, graft dysfunction and graft loss; this is not immunologic rejection.

Psychosocial complications, including anxiety, depression, loss of independence and social isolation, are frequent and often underestimated. The impact of chronic kidney disease and prolonged therapy on quality of life requires an integrated approach with psychological and social support.

Overall, management of MGRS complications is a fundamental part of care and requires close collaboration among nephrologists, hematologists, infectious disease specialists, cardiologists, nutrition specialists and other professionals to prevent irreversible damage, reduce morbidity and improve overall survival.

References
1. Leung N et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 120, 22, 2012, 4292-4295.
2. Fermand JP et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 122, 22, 2013, 3583-3590.
3. Bridoux F et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney International. 87, 4, 2015, 698-711.
4. Leung N et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology. 15, 1, 2019, 45-59.
5. Castillo JJ et al. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. American Journal of Hematology. 96, 7, 2021, 846-853.
6. Nasr SH et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney International. 65, 1, 2004, 85-96.
7. Lin J et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. Journal of the American Society of Nephrology. 12, 7, 2001, 1482-1492.
8. Joly F et al. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood. 133, 6, 2019, 576-587.
9. Ravindran A et al. Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney International. 91, 3, 2017, 691-698.
10. Cohen C et al. Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management. Diagnostics. 11, 3, 2021, 420.